CVS Health

CVS Health announced plans to separate its retail pharmacy business from its insurer Aetna and PBM Caremark, creating two publicly traded companies by the first half of 2028. Management cites improved retail profitability, stronger Aetna and Caremark performance, cost cuts and higher cash flow as reasons the units can stand alone. The split aims to let investors value each business independently, but raises questions about preserving commercial synergies, regulatory scrutiny of PBMs and potential impacts on Medicare Advantage relationships; shares fell about 12% on the news. » More on cnbc.com

CVS Health will separate its 9,000 retail pharmacies, in‑store clinics and mail‑order prescription business into a new company named CVS Pharmacy, while the remaining CVS Health will retain insurer Aetna, pharmacy benefits manager Caremark and care services. The move, planned for early 2028, responds to political and regulatory pressure over industry concentration and state laws targeting vertical integration. David Joyner will lead the healthcare solutions company that keeps Aetna and Caremark, as the group shifts away from the conglomerate structure after years of acquisitions. » More on theguardian.com

Polaris Global Equity Strategy highlighted CVS Health's June 2026 launch of a comprehensive GLP-1 program combining lower-cost access, pharmacist support and tailored OTC products, saying investors welcomed the strategy to capture share of the weight-loss market. The firm noted the Composite outperformed in health care with multiple holdings posting double-digit gains and reported CVS shares at $87.10 with a market cap of $111.4 billion as of September 22, 2026. » More on finance.yahoo.com

At the Wells Fargo Healthcare Conference, CVS presented a comprehensive turnaround strategy that includes tighter pricing, operational optimization and increased use of technology. Leverage fell from 5x in 2024 to the mid-3x range after $4 billion of debt paydown, with the BBB rating maintained. The Pharmacy & Consumer Wellness division is growing again in the mid-single digits, Caremark remains under pressure and the 340B program will weigh on 2025–2026; stabilization is expected by the end of 2026. CVS cites AI and digital projects as drivers of more than $1 billion in productivity gains, plans possible buybacks for 2026 and is relying on Oak Street Health to improve the portfolio over the long term. » More on de.investing.com

CVS Health has climbed over 18% year-to-date after three consecutive quarters of revenue and profit beats and repeated guidance raises. Stronger performance in its healthcare benefits segment, led by Aetna and a sharply lower medical benefit ratio, drove substantial increases in adjusted operating income. Analyst consensus price target sits at $114.59 (roughly 22% above the recent close) with most analysts rating the stock a buy, despite operational challenges at Caremark. Investors are pricing continued benefit-segment strength amid an aging U.S. population as the main growth driver. » More on finance.yahoo.com